Literature DB >> 3280914

Antiviral agents.

E D Reines1, P A Gross.   

Abstract

Potent effective antiviral drugs recently have been licensed for several viral diseases, ushering in a new era in the treatment of viral diseases. Several unique features in the process of a viral infection have been identified as target points for inhibition. The unique steps and the interfering compounds are the subject of this review.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3280914      PMCID： PMC7131553          DOI： 10.1016/s0025-7125(16)30766-0

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN： 0025-7125            Impact factor:   5.456


  84 in total

1.  Varicella-Zoster virus does not become more resistant to acyclovir during therapy.

Authors:  N L Cole; H H Balfour
Journal:  J Infect Dis       Date:  1986-03       Impact factor: 5.226

2.  Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon.

Authors:  F G Hayden; J K Albrecht; D L Kaiser; J M Gwaltney
Journal:  N Engl J Med       Date:  1986-01-09       Impact factor: 91.245

3.  Influenza: its control in persons and populations.

Authors:  R B Couch; J A Kasel; W P Glezen; T R Cate; H R Six; L H Taber; A L Frank; S B Greenberg; J M Zahradnik; W A Keitel
Journal:  J Infect Dis       Date:  1986-03       Impact factor: 5.226

4.  Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial.

Authors:  R C Reichman; G J Badger; G J Mertz; L Corey; D D Richman; J D Connor; D Redfield; M C Savoia; M N Oxman; Y Bryson
Journal:  JAMA       Date:  1984-04-27       Impact factor: 56.272

5.  Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure.

Authors:  H C Krasny; S H Liao; P de Miranda; O L Laskin; A Whelton; P S Lietman
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

6.  Effect of ribavirin on macromolecular synthesis in vesicular stomatitis virus-infected cells.

Authors:  P Toltzis; A S Huang
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

7.  Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T-cell lymphotropic virus (HTLV-III)/lymphadenopathy-associated virus (LAV).

Authors:  J Balzarini; H Mitsuya; E De Clercq; S Broder
Journal:  Int J Cancer       Date:  1986-03-15       Impact factor: 7.396

8.  Current status of amantadine and rimantadine as anti-influenza-A agents: memorandum from a WHO meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

9.  Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine.

Authors:  D Felsenstein; D J D'Amico; M S Hirsch; D A Neumeyer; D M Cederberg; P de Miranda; R T Schooley
Journal:  Ann Intern Med       Date:  1985-09       Impact factor: 25.391

10.  Ribavirin aerosol treatment of influenza B virus infection.

Authors:  H W McClung; V Knight; B E Gilbert; S Z Wilson; J M Quarles; G W Divine
Journal:  JAMA       Date:  1983-05-20       Impact factor: 56.272
View more
  8 in total

Review 1.  Rapid viral diagnosis in perspective.

Authors:  P C Lee; P Hallsworth
Journal:  BMJ       Date:  1990-06-02

Review 2.  Adverse effects and drug interactions of clinical importance with antiviral drugs.

Authors:  D J Morris
Journal:  Drug Saf       Date:  1994-04       Impact factor: 5.606

3.  A randomized, double-blind, placebo-controlled trial of interferon-alpha and amantadine versus interferon-alpha alone in the treatment of patients with chronic hepatitis C.

Authors:  Jawad Ahmad; Hugo Vargas; Vijayan Balan; Jorge Rakela; A Obaid Shakil
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.487

4.  Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety.

Authors:  Steven K Herrine; Robert S Brown; David E Bernstein; Michael S Ondovik; Ellen Lentz; Helen Te
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.487

5.  Inhibitory effects of ribavirin alone or combined with human alpha interferon on feline infectious peritonitis virus replication in vitro.

Authors:  R C Weiss; T Oostrom-Ram
Journal:  Vet Microbiol       Date:  1989-07       Impact factor: 3.293

6.  Approaches to antiviral drug development.

Authors:  W H Prusoff; T S Lin; E M August; T G Wood; M E Marongiu
Journal:  Yale J Biol Med       Date:  1989 Mar-Apr

7.  Evaluation of free or liposome-encapsulated ribavirin for antiviral therapy of experimentally induced feline infectious peritonitis.

Authors:  R C Weiss; N R Cox; M L Martinez
Journal:  Res Vet Sci       Date:  1993-09       Impact factor: 2.534

8.  Toxicologic effects of ribavirin in cats.

Authors:  R C Weiss; N R Cox; M K Boudreaux
Journal:  J Vet Pharmacol Ther       Date:  1993-09       Impact factor: 1.786
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.